After losing the bid for Metsera to Pfizer, Novo Nordisk AS CEO sets sights on new targets
According to informed sources, Novo Nordisk AS, the owner of Wegovy and Ozempic, will continue to focus on business opportunities in the fields of obesity, diabetes, and their related complications. The company has viewed Metsera Inc. as a potential complementary transaction rather than a transformative acquisition. Novo Nordisk AS stated in a statement that the company will "evaluate business development and acquisition opportunities that meet its return and capital allocation criteria and can further achieve its strategic goals."
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments